Frontlight ResearchEarly access
CompletedPhase 2
A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
Key facts
- Who runs it
- Priovant Therapeutics, Inc.
- Where
- Bellaire, Durham, Eugene, Katy, Lakewood, Los Angeles, Nashville, Palisades Park, Palo Alto, Pasadena, Plano, Salt Lake City, St Louis, Waltham, and Winston-Salem, United StatesSee the 15 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 26 people enrolled
- Started
- 14 Nov 2022
- Ended
- 30 Jul 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- Brepocitinib
- Record updated
- 25 July 2025
Who can take part
- Age
- 18 years to 74 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Adult subjects (18-74 years old)
- Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis)
- Active uveitic disease as defined by the presence of at least 1 of the following parameters in at least 1 eye, as determined by the investigator:; Active, inflammatory chorioretinal and/or retinal vascular lesion; OR; ≥2+ vitreous haze grade (NEI/SUN criteria)
- Receiving up to one non-corticosteroid, non-biologic, immunomodulatory therapy
- Weight > 40 kg with a body mass index < 40 kg/m2
Who cannot take part
- History of:; Any lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)
- At risk of thrombosis and cardiovascular disease
- Have active or recent infections; Other protocol defined Inclusion/Exclusion criteria may apply
- Has isolated anterior uveitis
- Has confirmed or suspected current diagnosis of infectious uveitis
- Have a high risk for herpes zoster reactivation
Where in United States
- Bellaire, TexasHospital not named in the registry
- Durham, North CarolinaHospital not named in the registry
- Eugene, OregonHospital not named in the registry
- Katy, TexasHospital not named in the registry
- Lakewood, ColoradoHospital not named in the registry
- Los Angeles, CaliforniaHospital not named in the registry
- Nashville, TennesseeHospital not named in the registry
- Palisades Park, New JerseyHospital not named in the registry
- Palo Alto, CaliforniaHospital not named in the registry
- Pasadena, CaliforniaHospital not named in the registry
- Plano, TexasHospital not named in the registry
- Salt Lake City, UtahHospital not named in the registry
- St Louis, MissouriHospital not named in the registry
- Waltham, MassachusettsHospital not named in the registry
- Winston-Salem, North CarolinaHospital not named in the registry
About the trial
What the trial wants to find out
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).
The 2 groups in the trial
- Brepocitinib Dose Level 1 by mouth (PO) once daily (QD)Treatment being tested
Treatment: Brepocitinib
- Brepocitinib Dose Level 2 by mouth (PO) once daily (QD)Treatment being tested
Treatment: Brepocitinib
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 2 Randomized, Double-Masked, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active Non-Infectious Intermediate-, Posterior-, and Panuveitis
- Record updated
- 25 July 2025